首页> 外文期刊>JAMA: the Journal of the American Medical Association >A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: Opportunities provided by a new IOM report
【24h】

A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: Opportunities provided by a new IOM report

机译:评估FDA批准方法和监管行动的生命周期方法:新的IOM报告提供的机会

获取原文
获取原文并翻译 | 示例
       

摘要

IN THE POSTMARKET SETTING, THE REGULATION OF MEDICINES requires an assessment of the balance between their benefits and risks and, as new information becomes available, may require regulatory actions that range from changes in the product label to withdrawal of a drug from the market. A series of unforeseen consequences of drug administration to vulnerable patients has shaped the modern history of the regulation of medications. In the 1960s, for instance, thalidomide given to pregnant women resulted in birth defects or death in several thousand of their offspring. The framework for modern drug regulation largely emerged from the development of various measures to prevent similar drug-safety disasters.
机译:在邮票环境中,药物的调节需要评估其利益和风险之间的平衡,因为新信息可用,可能需要监管行动,这些行动范围从产品标签的变化中撤离来自市场的药物。 药物管理局给弱势患者的一系列无法预料的后果,塑造了药物监管的现代历史。 例如,在20世纪60年代,给予孕妇的沙利度胺导致几千个后代的出生缺陷或死亡。 现代药物监管框架主要出现在各种措施的发展中,以防止类似的药物安全灾害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号